TABLE 4.
Are any of the following contextual considerations important in assessing the long-term value for money of dupilumab versus standard of care without biologics? | |
---|---|
Contextual Consideration | Panel Votesa |
Dupilumab is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life | 11 |
Dupilumab is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness. | 12 |
Dupilumab is the first to offer any improvement for patients with this condition | 0 |
There is significant uncertainty about the long-term risk of serious side effects of this intervention. | 8 |
There is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention. | 11 |
There are additional contextual considerations that should have an important role in judgements of the value of this intervention | 3 |
aFifteen panelists voted.